Arovella Therapeutics Limited · ASX:ALA

Arovella Therapeutics — Shareholder Meeting (April 2023)

15 slides from Arovella Therapeutics's shareholder meeting presentation, Apr 21, 2023

  1. Slide 1: Chairman's address and CEO's presentation to Extraordinary General Meeting

    ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX RELEASE 21 April 2023 For personal use only Chairman’s address and CEO’s presentation to Extraordinary General Meeting MELBOURNE, AUSTRALIA 21 April 2023: Arovella Therapeutics Limited (Arovella or the Company) (ASX: ALA), a biotechnology co

  2. Slide 2: Chairman's address

    ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Chairman’s address For personal use only Good morning ladies and gentlemen. My name is Thomas Duthy, and I am the Chairman of Arovella Therapeutics Limited. On behalf of the Arovella Board of Directors, I am pleased to welcome you to the Extraor

  3. Slide 3: Chairman's address (continued)

    ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 As mentioned, I am a believer in Board alignment with shareholders and being a careful guardian of shareholder’s equity and the capital provided to the Company which is otherwise loss making. Hence, I For personal use only elected to not receive

  4. Slide 4: Notes to editors: About Arovella Therapeutics

    ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd For personal use only Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing therapies to treat human diseases. Arovella is developing its invariant natural killer

  5. Slide 5: Extraordinary General Meeting April 2023

    For personal use only ASX: ALA EXTRAORDINARY GENERAL MEETING April 2023

  6. Slide 6: Disclaimer

    Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). For pers

  7. Slide 7: Arovella Board of Directors

    Arovella Board of Directors Dr. Tom Duthy Dr. Michael Baker Dr. Liz Stoner For personal use only CHAIRMAN CEO & MANAGING DIRECTOR DIRECTOR Mr. David Simmonds Dr. Debora Barton Mr. Gary Phillips DIRECTOR DIRECTOR DIRECTOR 3 © Copyright Arovella Therapeutics Ltd 2023

  8. Slide 8: Arovella Therapeutics Highlights

    Arovella Therapeutics Highlights For personal use only Allogeneic iNKT Cell Platform World Leading Partners Strong Leadership Group Arovella is developing off-the-shelf invariant Arovella’s technologies are licensed from Arovella’s leadership team and its Board Natural Killer T (iNKT) cell therapies

  9. Slide 9: Advantages of iNKT Cells

    Advantages of iNKT Cells Cells from a healthy donor can be used to For personal use only treat patients (no GvHD) Modify the tumour microenvironment and Naturally target tumour cells through iNKT cells kill cells that promote tumour growth subpopulation of T cells invariant TCR (CD1d); dual targetin

  10. Slide 10: The Potential of CAR-iNKT Cells is Untapped

    The Potential of CAR-iNKT Cells is Untapped For personal use only 6 © Copyright Arovella Therapeutics Ltd 2023 Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information

  11. Slide 11: Arovella's Key Milestones Over Months

    Arovella’s Key Milestones Over 18 Months Cell Therapy For personal use only Partner Discovery Lead Optimisation IND-Enabling Phase 1 CAR19-iNKT CD19 Expressing Lymphoma (ALA-101) ALA-101 + Solid Tumours onCARlytics Multiple Myeloma TNBC DKK1-CAR-iNKT (ALA-104) NSCLC Pancreatic TNBC – triple negative

  12. Slide 12: ALA-101 Scale-Up and Preparation for Clinical Material

    ALA-101 Scale-Up and Preparation for Clinical Material For personal use only Complete  Optimised viral vector to engineer the CAR with regulatory-friendly elements On track  Identify high-frequency iNKT cell donors Ongoing H1 2023 Optimise manufacturing process to produce clinical-grade material P

  13. Slide 13: New Data Presented at AACR 2023

    New Data Presented at AACR 2023 For personal use only Key Highlights:  iNKT cells could be well expanded  ALA-101 killed tumour cells that express CD19, including primary patient tumour cells  ALA-101 significantly extended the lifespan of mice with aggressive human B-Cell Acute Lymphoblastic Leu

  14. Slide 14: Arovella Financial Overview

    Arovella Financial Overview Financial Snapshot 45,000,000 $0.11 For personal use only ALA Price and Volume - 12 Months1 ASX CODE ALA 40,000,000 $0.10 Market capitalisation1 $50.6 million 35,000,000 $0.09 Shares on issue 755.5 million 30,000,000 $0.08 52-week low / high $0.020 / $0.105 $0.07 25,000,0

  15. Slide 15: Dr. Michael Baker, CEO & Managing Director

    For personal use only Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com © Copyright Arovella Therapeutics Ltd 2023

Arovella Therapeutics — Shareholder Meeting (April 2023) on 6ix